drugset / Trial / NCT07230730

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

NCT07230730 ↗

Phase 3 Recruiting 900 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.

Timeline

Start
2026-01-13
Primary completion
2027-10
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1918 Monoclonal antibody — —

Indications